Clinical Trials Logo

Clinical Trial Summary

Sickle cell disease (SCD) is characterized by an abnormal hemoglobin, the main protein in the red blood cell. From the first months of life, acute obstruction of the vessels of the microcirculation manifests as intense and unpredictable recurrent episodes of severe pain. In the Emergency Department (ED), patients presenting with a vaso-occlusive crisis (VOC) required a rapid evaluation and administration of pain relief therapies and hydration. this strategy is based on an intranasal (IN) administration of Sufentanil at the initial management of children with VOC, followed by morphine intravenous (IV) relay as soon as possible, compared to the usual care procedure with IV morphine as soon as possible. The hypothesis is that the use of this IN opioid at the beginning of the management of children with VOC can reduce the time before being pain relieved. Indeed, the IN administration make it easier and faster to administer.


Clinical Trial Description

Sufentanil is a powerful opioid analgesic used intravenously by emergency physicians for the sedation of intensive care, intubated and ventilated patients. It is therefore already present in the pharmacopoeia of emergencies. As the duration of action of inztranasal Sufentanil is too short to completely replace the IV morphine, a very promising approach would be to use it during the initial phase of the management of severe pain in children with painful sickle cell crisis while waiting for a venous access. The INVOPE trial is a phase III trial evaluating the intranasal sufentanil in sickle cell disease children with severe VOC. The INVOPE trial is a randomized controlled, multicenter, double blind, two parallel-group in a 1:1 ratio, placebo-controlled superiority trial comparing the analgesic efficacy of the sufentanil IN + standard care IV morphine / versus placebo IN + IV morphine as soon as possible. Children will be randomized in two groups: - Experimental group: IN Sufentanil procedure with IV administration of morphine as soon as possible - Control group : IN placebo IN procedure with IV administration of morphine as soon as possible The objective of this trial is to compare a procedure consisting in IN Sufentanil followed by IV morphine, when compared to IN placebo followed by IV morphine alone, in children with severe vaso-occlusive crisis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06181695
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Camille AUPIAIS, Per
Phone 01 48 02 55 55
Email camille.aupiais@aphp.fr
Status Not yet recruiting
Phase Phase 3
Start date May 2, 2024
Completion date May 29, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT03639805 - Music Therapy in Sickle Cell Disease Vaso-occlusive Crisis N/A
Withdrawn NCT00711698 - Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC) Phase 2
Recruiting NCT05289700 - Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) Phase 3
Recruiting NCT03412045 - Hyperbaric Oxygen Therapy in Sickle Cell Pain N/A
Recruiting NCT05376046 - Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)
Active, not recruiting NCT04935879 - A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises Phase 3
Terminated NCT01501643 - Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease N/A
Terminated NCT01891812 - Nitrous Oxide Analgesia Vaso-occlusive Crisis Phase 2
Completed NCT04301336 - Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia Phase 2/Phase 3
Completed NCT01737814 - Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) Phase 3
Completed NCT01419977 - Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo Phase 2
Completed NCT01119833 - Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis Phase 2
Recruiting NCT05378555 - Oral Ketamine for Treatment of Vaso-Occlusive Pain Phase 3
Completed NCT04756375 - Evaluation of Virtual Reality to Save Morphinic in the Treatment of Vaso-occlusive Seizures of Sickle Cell Patients Consulting in the Emergency Room N/A
Active, not recruiting NCT05348915 - A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Phase 3
Enrolling by invitation NCT06345638 - Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease
Completed NCT03296345 - Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis Phase 2
Terminated NCT02179177 - Apixaban in Patients With Sickle Cell Disease Phase 3
Recruiting NCT03353584 - Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease N/A
Terminated NCT01522196 - A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. Phase 2